Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: Involvement of serum- and glucocorticoid-regulated kinase type 1

Experimental Physiology

Volumn 97, Issue 6, 2012, Pages 710-718

  Martín Fernández, Beatriz ^a   de las Heras, Natalia ^a   Miana, María ^a   Ballesteros, Sandra ^a   Valero Muñoz, María ^a   Vassallo, Dalton ^b   Davel, Ana Paula ^c   Rossoni, Luciana Venturini ^d   Cachofeiro, Victoria ^a   Lahera, Vicente ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; INTERLEUKIN 1BETA; ISOPRENALINE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; XANTHINE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HEART; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEMODYNAMIC PARAMETERS; INFLAMMATION; MALE; NONHUMAN; OXIDATION; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 84862600933     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2011.063230     Document Type: Article

References (48)

1. Agabiti-Rosei E, Muiesan ML, Romanelli G, Castellano M, Beschi M, Alicandri C & Muiesan G (1987). Cardiac function as related to adrenergic activity in hypertensive left ventricular hypertrophy. J Clin Hypertens 3, 203-210.
2. BelAiba RS, Djordjevic T, Bonello S, Artunc F, Lang F, Hess J & Görlach A (2006). The serum- and glucocorticoid-inducible kinase Sgk-1 is involved in pulmonary vascular remodeling: role in redox-sensitive regulation of tissue factor by thrombin. Circ Res 98, 828-836.
3. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT & Clark WA (1989). Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 65, 657-670.
4. Bhargava A, Fullerton MJ, Myles K, Purdy TM, Funder JW, Pearce D & Cole TJ (2001). The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology 142, 1587-1594.
5. Bos R, Mougenot N, Findji L, Mediani O, Vanhoutte PM & Lechat P (2005). Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. J Cardiovasc Pharmacol 45, 8-13.
6. Bristow MR (2000). β-Adrenergic receptor blockade in chronic heart failure. Circulation 101, 558-569.
7. Cadenas E & Davies KJ (2000). Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 29, 222-230.
8. Chang HY, Klein RM & Kunos G (1982). Selective desensitization of cardiac beta adrenoceptors by prolonged in vivo infusion of catecholamines in rats. J Pharmacol Exp Ther 221, 784-789.
9. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB & Rector T (1984). Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311, 819-823.
10. Davel AP, Fukuda LE, De Sá LL, Munhoz CD, Scavone C, Sanz-Rosa D, Cachofeiro V, Lahera V & Rossoni LV (2008). Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. Am J Physiol Heart Circ Physiol 295, H211-H219.
11. Davel AP, Kawamoto EM, Scavone C, Vassallo DV & Rossoni LV (2006). Changes in vascular reactivity following administration of isoproterenol for 1 week: a role for endothelial modulation. Br J Pharmacol 148, 629-639.
12. Demura M, Wang F, Yoneda T, Karashima S, Mori S, Oe M, Kometani M, Sawamura T, Cheng Y, Maeda Y, Namiki M, Ino H, Fujino N, Uchiyama K, Tsubokawa T, Yamagishi M, Nakamura Y, Ono K, Sasano H, Demura Y & Takeda Y (2011). Multiple noncoding exons 1 of nuclear receptors NR4A family (nerve growth factor-induced clone B, Nur-related factor 1 and neuron-derived orphan receptor 1) and NR5A1 (steroidogenic factor 1) in human cardiovascular and adrenal tissues. J Hypertens 29, 1185-1195.
13. Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA & Garner HR (2008). Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice. J Pharmacol Exp Ther 324, 1196-1203.
14. Esler M & Kaye D (2000). Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 35, S1-S7.
15. Givertz MM, Sawyer DB & Colucci WS (2001). Antioxidants and myocardial contractility: illuminating the "dark side" of β-adrenergic receptor activation? Circulation 103, 782-783.
16. House SL, House BE, Glascock B, Kimball T, Nusayr E, Schultz JE & Doetschman T (2010). Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase 1. Mol Cell Pharmacol 2, 143-154.
17. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K & Takeshita A (1999). Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85, 357-363.
18. Kelm M, Schafer S, Mingers S, Heydthausen M, Vogt M, Motz W & Strauer BE (1996). Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 14, 1357-1364.
19. Kenakin TP & Ferris RM (1983). Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol. J Cardiovasc Pharmacol 5, 90-97.
20. Kim J, Eckhart AD, Eguchi S & Koch WJ (2002). β-Adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. J Biol Chem 277, 32116-32123.
21. Leenen FH (1999). Cardiovascular consequences of sympathetic hyperactivity. Can J Cardiol 15(Suppl A), 2A-7A.
22. Livak KJ & Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the method. Methods 25, 402-408.
23. Mann DL (1998). Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive. Prog Cardiovasc Dis 41, 1-8.
24. Martín-Fernández B, de las Heras N, Miana M, Ballesteros S, Delgado C, Song S, Hintze T, Cachofeiro V & Lahera V (2011). Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression. J Cardiovasc Pharmacol 57, 114-121.
25. Martin-Fernandez B, Miana M, De las Heras HN, Ruiz-Hurtado G, Fernandez-Velasco M, Bas M, Ballesteros S, Lahera V, Cachofeiro V & Delgado C (2009). Cardiac L-type calcium current is increased in a model of hyperaldosteronism in the rat. Exp Physiol 94, 675-683.
26. Murray DR, Prabhu SD & Chandrasekar B (2000). Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101, 2338-2341.
27. Myers SA, Eriksson N, Burow R, Wang SC & Muscat GE (2009). β-Adrenergic signaling regulates NR4A nuclear receptor and metabolic gene expression in multiple tissues. Mol Cell Endocrinol 309, 101-108.
28. Ni L, Zhou C, Duan Q, Lv J, Fu X, Xia Y & Wang DW (2011). β-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure. PLoS One 6, e27294.
29. Oliveira EM & Krieger JE (2005). Chronic β-adrenoceptor stimulation and cardiac hypertrophy with no induction of circulating renin. Eur J Pharmacol 520, 135-141.
30. Opie LH, Thandroyen FT, Muller C & Bricknell OL (1979). Adrenaline-induced "oxygen-wastage" and enzyme release from working rat heart. Effects of calcium antagonism, β-blockade, nicotinic acid and coronary artery ligation. J Mol Cell Cardiol 11, 1073-1094.
31. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J & Wittes J for the Randomized Aldactone Evaluation Study Investigators (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341, 709-717.
32. Rona G, Chappel CI, Balazs T & Gaudry R (1959). An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. AMA Arch Pathol 67, 443-455.
33. 1. Am J Physiol Heart Circ Physiol 283, H1253-H1262.
34. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F & Esler MD (2003). Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108, 560-565.
35. Shizukuda Y, Buttrick PM, Geenen DL, Borczuk AC, Kitsis RN & Sonnenblick EH (1998). β-Adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol Heart Circ Physiol 275, H961-H968.
36. Simko F & Simko J (1999). Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res 48, 1-8.
37. Song LF, Jiang W, Qing Y, Hu XH, Li Y, Tong QY & Wu XH (2011). The antagonistic effect of PI3K-gamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by isoproterenol in rats. [Article in Chinese.] Sichuan Da Xue Xue Bao Yi Xue Ban 42, 471-474.
38. Struthers AD & Macdonald TM (2004). Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61, 663-670.
39. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S & Sabbah HN (2002). Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106, 2967-2972.
40. Taylor PB & Tang Q (1984). Development of isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharmacol 62, 384-389.
41. Thomas JA & Marks BH (1978). Plasma norepinephrine in congestive heart failure. Am J Cardiol 41, 233-243.
42. Trapp T & Holsboer F (1995). Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem Biophys Res Commun 215, 286-291.
43. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T & Kinoshita M (2001). Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37, 1228-1233.
44. Vassallo DV, Vasquez EC & Cabral AM (1988). Contractile performance of papillary muscles of renovascular hypertensive and isoproterenol-pretreated rats. Pharmacol Res Commun 20, 61-72.
45. Virbasius JV, Song X, Pomerleau DP, Zhan Y, Zhou GW & Czech MP (2001). Activation of the Akt-related cytokine-independent survival kinase requires interaction of its phox domain with endosomal phosphatidylinositol 3-phosphate. Proc Natl Acad Sci U S A 98, 12908-12913.
46. Xie Z, Singh M & Singh K (2004). Differential regulation of matrix metalloproteinase-2 and 9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1β. J Biol Chem 279, 39513-39519.
47. Zannad F, Alla F, Dousset B, Perez A & Pitt B on behalf of the RALES Investigators (2000). Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 102, 2700-2706.
48. Zhao X, Wu N, Deng M, Yin Y, Zhou J, Fang Y & Huang L (2006). An improved method of left ventricular catheterization in rats. Physiol Meas 27, N27-N33.